XENETIC BIOSCIENCES, INC. Shareholders' Equity
XENETIC BIOSCIENCES, INC. (XBIO) had Shareholders' Equity of $6.07 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $6.07M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $6.95M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $7.40M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $3.96M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $6.07M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $6.95M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $7.40M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $3.96M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $4.45M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $5.12M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $6.01M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $7.04M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $7.45M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $8.68M 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $9.80M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $10.89M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $11.88M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $12.86M 10-Q · filed 2024-08-13 | |
| 2022-12-31 | $13.65M 10-K · filed 2025-03-18 | |
| 2022-09-30 | $14.52M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $15.19M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $16.92M 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $18.39M 10-K · filed 2024-03-21 | |
| 2021-09-30 | $20.16M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $9.95M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $10.95M 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $12.22M 10-K · filed 2023-03-22 | |
| 2020-09-30 | $7.91M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $15.36M 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $16.20M 10-Q · filed 2021-08-12 | |
| 2019-12-31 | $17.21M 10-K · filed 2022-03-22 | |
| 2019-09-30 | $18.26M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $10.39M 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $11.52M 10-Q · filed 2020-08-12 | |
| 2018-12-31 | $9.91M 10-K · filed 2021-03-16 | |
| 2018-09-30 | $11.30M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $12.78M 10-Q · filed 2019-11-14 | |
| 2018-03-31 | $12.89M 10-Q · filed 2019-08-14 | |
| 2017-12-31 | $14.30M 10-K · filed 2020-03-26 | |
| 2017-09-30 | $9.55M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $11.51M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $13.90M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $16.17M 10-K · filed 2019-03-29 | |
| 2016-09-30 | $5.95M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $6.41M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $5.06M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $6.61M 10-K · filed 2018-03-30 | |
| 2015-09-30 | $5.18M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | $6.83M 10-Q · filed 2015-08-19 | |
| 2015-03-31 | $8.21M 10-Q · filed 2015-05-20 | |
| 2014-12-31 | $10.48M 10-K · filed 2017-03-31 | |
| 2014-09-30 | $14.02M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $17.49M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $19.81M 10-Q · filed 2014-05-20 | |
| 2013-12-31 | $12.62M 10-K · filed 2016-03-30 | |
| 2013-11-30 | -$264.54K 10-Q · filed 2014-01-10 | |
| 2013-08-31 | -$182.08K 10-Q · filed 2014-01-10 | |
| 2013-05-31 | -$105.99K 10-Q · filed 2013-07-17 | |
| 2013-02-28 | -$92.31K 10-Q · filed 2013-04-22 | |
| 2012-12-31 | $20.78M 10-K · filed 2015-07-20 | |
| 2012-11-30 | -$107.39K 10-Q · filed 2013-01-22 | |
| 2012-08-31 | -$92.91K 10-K · filed 2013-11-27 | |
| 2012-05-31 | -$49.53K 10-Q · filed 2012-07-16 | |
| 2012-02-29 | -$45.67K 10-Q · filed 2012-04-24 | |
| 2011-12-31 | $14.80M 10-K · filed 2015-07-20 | |
| 2011-08-31 | -$92.91K 10-K · filed 2013-11-27 | $1.76K 10-Q · filed 2012-04-24 |
| 2011-08-08 | $1.76K 10-K · filed 2013-11-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |